NasdaqGM:ADMABiotechs
ADMA Biologics (ADMA) Is Up 7.2% After Raised Guidance and Share Buybacks Has the Bull Case Changed?
On November 5, 2025, ADMA Biologics reported third quarter results with sales of US$134.22 million and net income of US$36.43 million, alongside raising its 2025 and 2026 revenue guidance and providing a long-term outlook for US$1.1 billion or more in annual revenue by 2029.
The company's ongoing share repurchase program, coupled with an improved earnings forecast, highlights management's confidence in operational progress and future growth prospects.
With the company raising revenue...